Form 4 Filing for Cogent Biosciences, Inc. - Officer/Director Transaction

Karen Jean Ferrante, a director at Cogent Biosciences, Inc., was granted 686 stock options on April 1, 2026. These options, with an exercise price of $35.24, were received in lieu of cash compensation for her services as a director. The value of these options is tied to the Black-Scholes value calculated at the time of the grant. Ms. Ferrante elected to receive shares instead of cash, as permitted by the company's non-employee director compensation plan. Following this transaction, Ms. Ferrante directly owns 686 shares underlying these options.